AHA on NSAID use
This article was originally published in The Tan Sheet
Executive Summary
"Many doctors should change the way they prescribe pain relievers for chronic pain in patients with or at risk for heart disease," the American Heart Association says in a Feb. 26 news release. The release announces a Scientific Statement appearing in the journal Circulation Feb. 27, which advises physicians to prescribe drugs only if non-pharmacologic treatments are unsuccessful. "When acetaminophen, aspirin and perhaps even narcotic medications are not effective ... it may be reasonable to consider an NSAID as the next step," Elliot M. Antman, M.D., Harvard Medical School and Brigham and Women's Hospital, et al., conclude. "If symptoms are not adequately controlled by a nonselective NSAID, subsequent steps involve prescription of drugs with increasing degrees of COX-2 inhibitory activity, ultimately concluding with the COX-2 selective NSAIDs." The authors say naproxen "appears to be the preferred choice" in terms of NSAID treatments, but note that "relatively few" studies have been conducted on the drug...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.